News and Media

Tchaikapharma High Quality Medicines is one of the fastest-growing Bulgarian pharmaceutical companies, producing generic medicinal products. Its revenues at the end of the third quarter amounted to BGN 47.94 million, compared to BGN 40.41 million a year earlier. The company’s net profit reached BGN 6.6 million, marking an annual increase of 51.89%, according to the figures in its interim financial report.

Tchaikapharma High Quality Medicines is one of the fastest-growing Bulgarian pharmaceutical companies, producing generic medicinal products. Its revenues at the end of the third quarter amounted to BGN 47.94 million, compared to BGN 40.41 million a year earlier. The company’s net profit reached BGN 6.6 million, marking an annual increase of 51.89%, according to the figures in its interim financial report.

Tablets hold the largest share of sales, generating BGN 36.88 million in revenue, followed by vials and ampoules.

The company has invested in the purchase of a machine for visual inspection of each vial, aimed at optimizing the production process and accelerating product release. The installation at the company’s Varna plant has been completed, and the machine has been put into operation.

Operating expenses have also increased — reaching BGN 40.55 million, compared to BGN 35.64 million for the same nine-month period last year. The largest expenses were for materials and external services. Wage costs rose to BGN 6.63 million, up from BGN 5.59 million a year earlier.

The company’s main business activities currently include production, primary and secondary packaging, marketing and promotion of pharmaceuticals, and research and development.

At present, the company’s factories manufacture over 160 medicinal products and eight dietary supplements.

In September, the pharmaceutical company increased its share capital from BGN 91,800,000 to BGN 95,900,000 using own funds. The new ordinary, registered, dematerialized voting shares with a nominal value of BGN 1 each have been traded on the Bulgarian Stock Exchange since September 26.

Over the past twelve months, the company’s shares on the BSE have risen to BGN 17.90 per share, bringing its market capitalization to BGN 1,716,610,000 – making it the second-largest public company on the Bulgarian Stock Exchange – Sofia.

Tchaikapharma High Quality Medicines reported a 19.61% increase in sales revenue for the first half of the year, reaching BGN 32.11 million. Net profit as of the end of June stood at BGN 4.78 million, up from BGN 2.81 million in the same period last year, according to the company’s financial report for the second quarter.

The bulk of the revenue came from oral solid medicines sales, which generated BGN 25.64 million.

Operating expenses, which are primarily related to the production and distribution of medicinal products, totaled BGN 27 million. The largest cost components were materials, external services, and employee remuneration.

Tchaikapharma is among the fastest-growing pharmaceutical companies in Bulgaria, specializing in the production of high-quality, affordable generic medicines. Its manufacturing facilities in Varna and Plovdiv currently produce over 160 medicinal products. To meet growing demand, the company expanded its workforce to 216 employees by the end of June, up from 207 in December.

Therapeutic solutions ensure good control of cardiovascular diseases and increase patients’ quality of life

According to the data of the National Health Insurance Fund for the third quarter of the last year, Tchaikapharma’s medicinal product “Zornichka” with active ingredient (INN) chlorthalidone marked an increase in the number of packages sold by nearly 95% (compared to the same period in 2023), reaching 40 thousand packages. “Zornicka” belongs to a group of medicines called thiazide diuretics (“dehydrating tablets”).

“Doxazosin-Tchaikapharma also ranks among the top performers with the largest market share in the group of so-called “alpha blockers” used to treat high blood pressure (hypertension) or symptoms due to an enlargement of the prostate gland (benign prostatic hyperplasia ) with more than 62 thousand packs sold.

The huge palette of nearly 50 medicinal products manufactured by Tchaikapharma High Quality Medicines Inc. for the treatment of cardiovascular diseases guarantees a wide therapeutic choice for specialists in the treatment of hypertension, atherosclerosis, dyslipidemias, heart attacks, thrombosis and coronary artery disease. For years, cardiovascular disease has been the number one cause of death in Bulgaria and has been identified as one of the most socially significant diseases due to its high rate of disability and reduced work capacity. For 25 years Tchaikapharma has been improving the quality of life of Bulgarian families by providing affordable modern therapeutic solutions.

Once again, Tchaikapharma High Quality Medicines participated in the National Conference on Hospital Pharmacy held in Sofia from 18-20 October 2024. The leading Bulgarian manufacturer of complex generics (polypills) presented its new products for the treatment of socially significant diseases such as cerebrovascular disease, Parkinson’s disease, impaired metabolic syndrome, angina pectoris, arterial hypertension and heart failure. The stable supply chains established over the years and modern production conditions complying with the highest European standards guarantee continuity of therapeutic intake for Bulgarian and European patients.

The conference, organized by the Bulgarian Association of Hospital and Clinical Pharmacists, was held for the eighteenth consecutive year. It brought together representatives of the leading pharmaceutical companies as well as Master Pharmacists from all over the country.

Tchaikapharma has received marketing authorization for a new medicinal product:

Telmira 60 mg film-coated tablets
Telmira 90 mg film-coated tablets

Telmira contains a medicinal substance called ticagrelor. It belongs to a group of medicines called antithrombotic medicines.

Telmira, given at the same time as acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with:

– acute coronary syndrome (ACS) or

– a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.

The medicinal product is available on prescription.
ATC code: B01AC24